GSK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 23:19):

Stats
今日成交量	1.55M
平均成交量	3.45M
市值	87.38B
EPS	$0 ( 2024-05-01 )
下一个收益日期	( $0 ) 2024-07-31
Last Dividend	$0.340 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	14.35
ATR14	$0.0250 (0.06%)

音量相关性

長: -0.26 (neutral)

短: -0.36 (neutral)

Signal:(49.947) Neutral

GlaxoSmithKline PLC 相关性

10 最正相关

10 最负相关
YSAC	-0.891

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

GlaxoSmithKline PLC 相关性 - 货币/商品

-0.17
( neutral )

-0.50
( weak negative )

-0.59
( weak negative )

-0.27
( neutral )

-0.76
( moderate negative )

0.54
( weak )

GlaxoSmithKline PLC 财务报表

Annual	2023
营收:	$30.33B
毛利润:	$21.25B (70.07 %)
EPS:	$1.220

FY	2023
营收:	$30.33B
毛利润:	$21.25B (70.07 %)
EPS:	$1.220

FY	2022
营收:	$29.32B
毛利润:	$19.77B (67.42 %)
EPS:	$1.220

FY	2021
营收:	$34.11B
毛利润:	$22.51B (65.99 %)
EPS:	$2.19

Financial Reports:

No articles found.

GlaxoSmithKline PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.391 (N/A)	$0.317 (N/A)	$0.340 (N/A)	$0.348 (N/A)	$0.361 (N/A)	$0.340 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

GlaxoSmithKline PLC Dividend Information - Dividend King

Dividend Sustainability Score: 9.66 - good (96.56%) | Divividend Growth Potential Score: 7.25 - Increase likely (45.09%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0420	1987-05-15
Last Dividend	$0.340	2023-11-16
Next Dividend	$0	N/A
Payout Date	2024-01-11
Next Payout Date	N/A
# dividends	120	--
Total Paid Out	$57.37	--
Avg. Dividend % Per Year	2.89%	--
Score	6.19	--
Div. Sustainability Score	9.66
Div.Growth Potential Score	7.25
Div. Directional Score	8.46	--

Next Divdend (Est)
(2024-06-03)

$0.335 Estimate 38.07 %

Dividend Stability

0.76 Good

Dividend Score

6.19

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1987	$0.184	2.39%
1988	$0.135	1.42%
1989	$0.319	3.31%
1990	$0.468	3.63%
1991	$0.567	3.45%
1992	$0.861	2.70%
1993	$0.363	1.52%
1994	$1.027	4.86%
1995	$1.159	5.55%
1996	$1.164	4.14%
1997	$1.218	3.88%
1998	$1.148	2.39%
1999	$1.134	1.60%
2000	$2.03	3.65%
2001	$0.854	1.53%
2002	$1.889	3.79%
2003	$1.368	3.55%
2004	$1.604	3.43%
2005	$1.527	3.22%
2006	$1.738	3.41%
2007	$2.06	3.83%
2008	$2.14	4.27%
2009	$1.855	5.02%
2010	$1.998	4.65%
2011	$2.21	5.62%
2012	$2.48	5.35%
2013	$2.41	5.46%
2014	$2.65	5.02%
2015	$2.45	5.78%
2016	$2.77	6.85%
2017	$2.06	5.31%
2018	$2.16	5.85%
2019	$2.05	5.40%
2020	$2.06	4.39%
2021	$2.21	5.85%
2022	$1.680	3.85%
2023	$1.389	3.94%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.162	1.500	6.75	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0835	1.200	7.22	8.66	[0 - 0.3]
returnOnEquityTTM	0.387	1.500	6.82	10.00	[0.1 - 1]
payoutRatioTTM	0.456	-1.000	5.44	-5.44	[0 - 1]
currentRatioTTM	0.885	0.800	-0.575	-0.460	[1 - 3]
quickRatioTTM	0.597	0.800	-1.192	-0.954	[0.8 - 2.5]
cashRatioTTM	0.139	1.500	-0.337	-0.505	[0.2 - 2]
debtRatioTTM	0.288	-1.500	5.21	-7.81	[0 - 0.6]
interestCoverageTTM	9.12	1.000	7.73	7.73	[3 - 30]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.035	2.00	9.48	10.00	[0 - 20]
debtEquityRatioTTM	1.271	-1.500	4.92	-7.37	[0 - 2.5]
grossProfitMarginTTM	0.720	1.000	1.330	1.330	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.24	7.24	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.386	1.000	8.97	8.97	[0.2 - 2]
assetTurnoverTTM	0.514	0.800	9.91	7.93	[0.5 - 2]
Total Score				9.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	27.96	1.000	7.28	0	[1 - 100]
returnOnEquityTTM	0.387	2.50	7.95	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.035	2.00	9.65	10.00	[0 - 30]
dividendYielPercentageTTM	4.28	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
payoutRatioTTM	0.456	1.500	5.44	-5.44	[0 - 1]
pegRatioTTM	0.515	1.500	9.90	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.216	1.000	7.11	0	[0.1 - 0.5]
Total Score				7.25

GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.